Aimovig(erenumab)
Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Aimovig
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aimovig | Biologic Licensing Application | 2023-05-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 7 | 2 | 9 | 17 | 10 | 45 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | 1 | — | 1 |
| Facial pain | D005157 | — | R51.9 | — | — | — | 1 | — | 1 |
| Rhinosinusitis | D000096825 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic headache | D051298 | — | G44.3 | — | 3 | — | — | — | 3 |
| Brain concussion | D001924 | — | S06.0 | — | 2 | — | — | — | 2 |
| Temporomandibular joint disorders | D013705 | — | M26.6 | — | 2 | — | — | — | 2 |
| Rosacea | D012393 | — | L71 | — | 1 | — | — | — | 1 |
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | — | 1 | — | — | — | 1 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | 1 | — | — | — | 1 |
| Stable angina | D060050 | — | I20.89 | — | 1 | — | — | — | 1 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 1 | — | — | — | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | 1 | — | — | — | 1 |
| Primary headache disorders | D051270 | — | G44.53 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Hot flashes | D019584 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 4 | 4 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 2 | 2 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Erenumab |
| INN | erenumab |
| Description | Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6UMH:H,h|erenumab Fab heavy chain, IgG1
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLF
LQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDEVD
>6UMH:L,l|erenumab Fab light chain, IgG1
QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQ
TGDEADYYCGTWDSRLSAVVFGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVK
AGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS |
Identifiers
| PDB | 6UMG, 6UMH, 6UMI, 6UMJ |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3833329 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14039 |
| UNII ID | I5I8VB78VT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CALCRL
CALCRL
Organism
Homo sapiens
Gene name
CALCRL
Gene synonyms
CGRPR
NCBI Gene ID
Protein name
calcitonin gene-related peptide type 1 receptor
Protein synonyms
calcitonin receptor-like, Calcitonin receptor-like receptor, CGRP type 1 receptor
Uniprot ID
Mouse ortholog
Calcrl (54598)
calcitonin gene-related peptide type 1 receptor (Q9WUP2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Aimovig – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Erenumab
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,310 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
31,520 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use